Drug intelligence / Profile preview

BL-0330

Development stage: Preclinical
Lead developer: Shanghai Bestlink Biotechnology

Overview

BL-0330 is an oncology drug candidate currently in the discovery stage of development by Shanghai Best-Link Bioscience. It is being developed for the treatment of solid tumors. Due to its early stage of development, the specific molecular target, mechanism of action, and therapeutic modality (such as small molecule or drug conjugate) have not yet been publicly disclosed by the developer. The asset is part of Shanghai Best-Link Bioscience's pipeline, which focuses on small molecule drugs and drug conjugates for advanced malignant neoplasms.

Beyond the preview

Go deeper on BL-0330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-0330.

Explore the full profile